Janssen to acquire skin disease drug candidate bermekimab from XBiotech

Janssen to acquire skin disease drug candidate bermekimab from XBiotech

Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin disorders, from XBiotech, in a deal worth up to $1.35 billion, as per the latest pharma acquisition news. Bermekimab, which is an anti-IL-1alpha monoclonal antibody (mAb), […]

Janssen bags Stelara FDA approval for ulcerative colitis treatment

Janssen bags Stelara FDA approval for ulcerative colitis treatment

Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged approval from the US Food and Drug Administration (FDA) for Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis. Considered to be a serious, chronic and progressive immune-mediated inflammatory disease of the large intestine, […]

Janssen bags Xarelto FDA approval to prevent blood clots in acutely ill patients

Janssen bags Xarelto FDA approval to prevent blood clots in acutely ill patients

Xarelto FDA approval : The Janssen Pharmaceutical Companies of Johnson & Johnson has secured approval from the US Food and Drug Administration (FDA) for Xarelto (rivaroxaban) for the prevention of venous thromboembolism or blood clots in acutely ill medical patients. The latest approval for the drug is for the treatment of blood clots in hospitalized […]

Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint

Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint

Ponesimod OPTIMUM trial results :  Johnson & Johnson’s Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to Aubagio (teriflunomide) in adults having relapsing multiple sclerosis (MS). The OPTIMUM clinical trial, which enrolled 1,133 participants, assessed the efficacy and safety of the selective sphingosine-1-phosphate receptor 1 (S1P1) modulator […]

Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment

Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment

Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has received approval from the US Food and Drug Administration (FDA) for its combination treatment of IMBRUVICA (ibrutinib) and rituximab for Waldenström’s macroglobulinemia (WM), a rare form of blood cancer. This latest approval expands the use of IMBRUVICA in treating WM from monotherapy to now include combination […]